Health Care

New Treatment for Non-Hodgkin Lymphoma Approved

WEDNESDAY, Aug. 8, 2018 (HealthDay News) — Poteligeo (mogamulizumab) injection has been approved by the U.S. Food and Drug Administration to treat adults with two types of non-Hodgkin lymphoma.

The drug was approved to treat relapsed or refractory mycosis fungoides (MF) and Sézary syndrome (SS) after the patient has had at least one prior therapy delivered through the bloodstream.

“Mycosis fungoides and Sézary syndrome are rare, hard-to-treat types of non-Hodgkin lymphoma and this approval fills an unmet medical need for these patients,” Dr. Richard Pazdur, director of the FDA’s Oncology Center of Excellence, said in an agency news release.

Non-Hodgkin lymphoma is a cancer that starts in immune-boosting white blood cells called lymphocytes. When these cells become cancerous, the skin develops itchy rashes and lesions that may spread beyond the original site.

Poteligeo’s approval was based on clinical studies involving 372 people with relapsed MF or SS, who were given either Poteligeo or a chemotherapy drug called vorinostat. Progression-free survival averaged 7.6 months for those who took Poteligeo, versus 3.1 months among those who took vorinostat, the agency said Wednesday.

Poteligeo’s most common side effects included rash, injection-site reactions, fatigue, diarrhea, bone/muscle pain and respiratory tract infections. More serious side effects could include toxic skin reactions, autoimmune reactions and infections, the FDA said.

The drug is produced by the Japanese drugmaker Kyowa Kirin Inc.

— Scott Roberts

MedicalNews
Copyright © 2018 HealthDay. All rights reserved.


Women's Cancer: 15 Cancer Symptoms Women Ignore

15 Cancer Symptoms Women Ignore Slideshow


Men's Cancer: 15 Cancer Symptoms Men Ignore

Cancer Symptoms Men Ignore Slideshow


Take the Superfoods Quiz

Article source: http://www.medicinenet.com/script/main/art.asp?articlekey=214092

Loading...

Best Wordpress Plugin development company in India     Best Web development company in India

Related posts

Health Tip: Planning a Stress-Reducing Vacation

Times of News

Pricey Wines Can Trick Your Brain

Times of News

Teething Jewelry Linked to at Least One Baby’s Death: FDA

Times of News